Passage through the ocular barriers and beneficial effects in retinal ischemia of topical application of PACAP1-38 in rodents

Dora Werling, William A. Banks, Therese S. Salameh, Timea Kvarik, Laszloakos Kovacs, Alexandra Vaczy, Edina Szabo, Flora Mayer, Rita Varga, A. Tamás, G. Tóth, Zsolt Biro, Tamas Atlasz, D. Reglodi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The neuropeptide pituitary adenylate cyclase activating polypeptide (PACAP) has two active forms, PACAP1-27 and PACAP1-38. Among the well-established actions are PACAP’s neurotrophic and neuroprotective effects, which have also been proven in models of different retinopathies. The route of delivery is usually intravitreal in studies proving PACAP’s retinoprotective effects. Recently, we have shown that PACAP1-27 delivered as eye drops in benzalkonium-chloride was able to cross the ocular barriers and exert retinoprotection in ischemia. Since PACAP1-38 is the dominant form of the naturally occurring PACAP, our aim was to investigate whether the longer form is also able to cross the barriers and exert protective effects in permanent bilateral common carotid artery occlusion (BCCAO), a model of retinal hypoperfusion. Our results show that radioactive PACAP1-38 eye drops could effectively pass through the ocular barriers to reach the retina. Routine histological analysis and immunohistochemical evaluation of the Müller glial cells revealed that PACAP1-38 exerted retinoprotective effects. PACAP1-38 attenuated the damage caused by hypoperfusion, apparent in almost all retinal layers, and it decreased the glial cell overactivation. Overall, our results confirm that PACAP1-38 given in the form of eye drops is a novel protective therapeutic approach to treat retinal diseases.

Original languageEnglish
Article number675
JournalInternational Journal of Molecular Sciences
Volume18
Issue number3
DOIs
Publication statusPublished - Mar 21 2017

Fingerprint

Pituitary Adenylate Cyclase-Activating Polypeptide
ischemia
rodents
Ophthalmic Solutions
Rodentia
Ischemia
polypeptides
Neuroglia
Benzalkonium Compounds
Esotropia
Retinal Diseases
retina
occlusion
Common Carotid Artery
Neuroprotective Agents
arteries
Neuropeptides
Retina
delivery
chlorides

Keywords

  • Carotid artery occlusion
  • Eye drops
  • Ischemic retinopathy
  • Neuroprotection
  • PACAP

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Computer Science Applications
  • Spectroscopy
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Passage through the ocular barriers and beneficial effects in retinal ischemia of topical application of PACAP1-38 in rodents. / Werling, Dora; Banks, William A.; Salameh, Therese S.; Kvarik, Timea; Kovacs, Laszloakos; Vaczy, Alexandra; Szabo, Edina; Mayer, Flora; Varga, Rita; Tamás, A.; Tóth, G.; Biro, Zsolt; Atlasz, Tamas; Reglodi, D.

In: International Journal of Molecular Sciences, Vol. 18, No. 3, 675, 21.03.2017.

Research output: Contribution to journalArticle

Werling, Dora ; Banks, William A. ; Salameh, Therese S. ; Kvarik, Timea ; Kovacs, Laszloakos ; Vaczy, Alexandra ; Szabo, Edina ; Mayer, Flora ; Varga, Rita ; Tamás, A. ; Tóth, G. ; Biro, Zsolt ; Atlasz, Tamas ; Reglodi, D. / Passage through the ocular barriers and beneficial effects in retinal ischemia of topical application of PACAP1-38 in rodents. In: International Journal of Molecular Sciences. 2017 ; Vol. 18, No. 3.
@article{e270a178633c47ba952ea26ed69efe73,
title = "Passage through the ocular barriers and beneficial effects in retinal ischemia of topical application of PACAP1-38 in rodents",
abstract = "The neuropeptide pituitary adenylate cyclase activating polypeptide (PACAP) has two active forms, PACAP1-27 and PACAP1-38. Among the well-established actions are PACAP’s neurotrophic and neuroprotective effects, which have also been proven in models of different retinopathies. The route of delivery is usually intravitreal in studies proving PACAP’s retinoprotective effects. Recently, we have shown that PACAP1-27 delivered as eye drops in benzalkonium-chloride was able to cross the ocular barriers and exert retinoprotection in ischemia. Since PACAP1-38 is the dominant form of the naturally occurring PACAP, our aim was to investigate whether the longer form is also able to cross the barriers and exert protective effects in permanent bilateral common carotid artery occlusion (BCCAO), a model of retinal hypoperfusion. Our results show that radioactive PACAP1-38 eye drops could effectively pass through the ocular barriers to reach the retina. Routine histological analysis and immunohistochemical evaluation of the M{\"u}ller glial cells revealed that PACAP1-38 exerted retinoprotective effects. PACAP1-38 attenuated the damage caused by hypoperfusion, apparent in almost all retinal layers, and it decreased the glial cell overactivation. Overall, our results confirm that PACAP1-38 given in the form of eye drops is a novel protective therapeutic approach to treat retinal diseases.",
keywords = "Carotid artery occlusion, Eye drops, Ischemic retinopathy, Neuroprotection, PACAP",
author = "Dora Werling and Banks, {William A.} and Salameh, {Therese S.} and Timea Kvarik and Laszloakos Kovacs and Alexandra Vaczy and Edina Szabo and Flora Mayer and Rita Varga and A. Tam{\'a}s and G. T{\'o}th and Zsolt Biro and Tamas Atlasz and D. Reglodi",
year = "2017",
month = "3",
day = "21",
doi = "10.3390/ijms18030675",
language = "English",
volume = "18",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "3",

}

TY - JOUR

T1 - Passage through the ocular barriers and beneficial effects in retinal ischemia of topical application of PACAP1-38 in rodents

AU - Werling, Dora

AU - Banks, William A.

AU - Salameh, Therese S.

AU - Kvarik, Timea

AU - Kovacs, Laszloakos

AU - Vaczy, Alexandra

AU - Szabo, Edina

AU - Mayer, Flora

AU - Varga, Rita

AU - Tamás, A.

AU - Tóth, G.

AU - Biro, Zsolt

AU - Atlasz, Tamas

AU - Reglodi, D.

PY - 2017/3/21

Y1 - 2017/3/21

N2 - The neuropeptide pituitary adenylate cyclase activating polypeptide (PACAP) has two active forms, PACAP1-27 and PACAP1-38. Among the well-established actions are PACAP’s neurotrophic and neuroprotective effects, which have also been proven in models of different retinopathies. The route of delivery is usually intravitreal in studies proving PACAP’s retinoprotective effects. Recently, we have shown that PACAP1-27 delivered as eye drops in benzalkonium-chloride was able to cross the ocular barriers and exert retinoprotection in ischemia. Since PACAP1-38 is the dominant form of the naturally occurring PACAP, our aim was to investigate whether the longer form is also able to cross the barriers and exert protective effects in permanent bilateral common carotid artery occlusion (BCCAO), a model of retinal hypoperfusion. Our results show that radioactive PACAP1-38 eye drops could effectively pass through the ocular barriers to reach the retina. Routine histological analysis and immunohistochemical evaluation of the Müller glial cells revealed that PACAP1-38 exerted retinoprotective effects. PACAP1-38 attenuated the damage caused by hypoperfusion, apparent in almost all retinal layers, and it decreased the glial cell overactivation. Overall, our results confirm that PACAP1-38 given in the form of eye drops is a novel protective therapeutic approach to treat retinal diseases.

AB - The neuropeptide pituitary adenylate cyclase activating polypeptide (PACAP) has two active forms, PACAP1-27 and PACAP1-38. Among the well-established actions are PACAP’s neurotrophic and neuroprotective effects, which have also been proven in models of different retinopathies. The route of delivery is usually intravitreal in studies proving PACAP’s retinoprotective effects. Recently, we have shown that PACAP1-27 delivered as eye drops in benzalkonium-chloride was able to cross the ocular barriers and exert retinoprotection in ischemia. Since PACAP1-38 is the dominant form of the naturally occurring PACAP, our aim was to investigate whether the longer form is also able to cross the barriers and exert protective effects in permanent bilateral common carotid artery occlusion (BCCAO), a model of retinal hypoperfusion. Our results show that radioactive PACAP1-38 eye drops could effectively pass through the ocular barriers to reach the retina. Routine histological analysis and immunohistochemical evaluation of the Müller glial cells revealed that PACAP1-38 exerted retinoprotective effects. PACAP1-38 attenuated the damage caused by hypoperfusion, apparent in almost all retinal layers, and it decreased the glial cell overactivation. Overall, our results confirm that PACAP1-38 given in the form of eye drops is a novel protective therapeutic approach to treat retinal diseases.

KW - Carotid artery occlusion

KW - Eye drops

KW - Ischemic retinopathy

KW - Neuroprotection

KW - PACAP

UR - http://www.scopus.com/inward/record.url?scp=85016134925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016134925&partnerID=8YFLogxK

U2 - 10.3390/ijms18030675

DO - 10.3390/ijms18030675

M3 - Article

C2 - 28335564

AN - SCOPUS:85016134925

VL - 18

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 3

M1 - 675

ER -